- Home
- BLIN vs APRE Comparison
BLIN vs APRE Comparison
Compare BLIN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- APRE
- Stock Information
- Founded
- BLIN 2000
- APRE 2006
- Country
- BLIN United States
- APRE United States
- Employees
- BLIN N/A
- APRE N/A
- Industry
- BLIN EDP Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLIN Technology
- APRE Health Care
- Exchange
- BLIN Nasdaq
- APRE Nasdaq
- Market Cap
- BLIN 15.0M
- APRE 13.5M
- IPO Year
- BLIN 2007
- APRE 2019
- Fundamental
- Price
- BLIN $1.51
- APRE $1.75
- Analyst Decision
- BLIN Strong Buy
- APRE Strong Buy
- Analyst Count
- BLIN 1
- APRE 2
- Target Price
- BLIN $4.62
- APRE $15.50
- AVG Volume (30 Days)
- BLIN 71.4K
- APRE 23.0K
- Earning Date
- BLIN 05-13-2025
- APRE 05-13-2025
- Dividend Yield
- BLIN N/A
- APRE N/A
- EPS Growth
- BLIN N/A
- APRE N/A
- EPS
- BLIN N/A
- APRE N/A
- Revenue
- BLIN $15,394,000.00
- APRE $1,502,581.00
- Revenue This Year
- BLIN $7.71
- APRE N/A
- Revenue Next Year
- BLIN $6.98
- APRE N/A
- P/E Ratio
- BLIN N/A
- APRE N/A
- Revenue Growth
- BLIN N/A
- APRE 157.63
- 52 Week Low
- BLIN $0.76
- APRE $1.74
- 52 Week High
- BLIN $2.80
- APRE $6.48
- Technical
- Relative Strength Index (RSI)
- BLIN 59.68
- APRE 27.73
- Support Level
- BLIN $1.36
- APRE $1.74
- Resistance Level
- BLIN $2.16
- APRE $2.30
- Average True Range (ATR)
- BLIN 0.16
- APRE 0.15
- MACD
- BLIN 0.05
- APRE -0.01
- Stochastic Oscillator
- BLIN 46.25
- APRE 10.89
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.